# OnCo record paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005" ;
  schema:name "EGFR mutation and resistance of non-small-cell lung cancer to gefitinib"@en ;
  schema:description "One patient, two years in complete remission on gefitinib, then relapse. Sequencing the new biopsy found a second mutation in the same gene, at position 790, that stopped the drug binding."@en ;
  schema:url <https://onco.cc/key-papers/paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa044238>, <https://pubmed.ncbi.nlm.nih.gov/15728811/>, <https://doi.org/10.1056/NEJMoa044238> ;
  onco:tag "lung-evidence" ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa044238> ;
  schema:datePublished "2005"^^xsd:gYear ;
  schema:author "Kobayashi S, Boggon TJ, Dayaram T, et al." ;
  onco:related <https://onco.cc/key-papers/paper-lynch-egfr-activating-mutations-gefitinib-nejm-2004/>, <https://onco.cc/key-papers/paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011/>, <https://onco.cc/key-papers/paper-osimertinib-nsclc-n-engl-j-med-2017/>, <https://onco.cc/biomarkers/egfr-t790m/> ;
  onco:cancers <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/terms/ngs/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/gefitinib/>, <https://onco.cc/drugs/osimertinib/> ;
  onco:institutions <https://onco.cc/institutions/dana-farber/> ;
  onco:pathways <https://onco.cc/pathways/rtk-activation/>, <https://onco.cc/pathways/resistance-routes-map/> ;
  onco:terms <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/terms/egfr-mutation-subtypes/> ;
  onco:people <https://onco.cc/people/pasi-janne/>, <https://onco.cc/people/matthew-meyerson/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-resistance/>, <https://onco.cc/bottlenecks/b-tumor-heterogeneity/> ;
  onco:journals <https://onco.cc/journals/nejm/> .